- Home
- ELAB vs INDP Comparison
ELAB vs INDP Comparison
Compare ELAB & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- INDP
- Stock Information
- Founded
- ELAB 2020
- INDP 2000
- Country
- ELAB United States
- INDP United States
- Employees
- ELAB N/A
- INDP N/A
- Industry
- ELAB
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- INDP Health Care
- Exchange
- ELAB Nasdaq
- INDP Nasdaq
- Market Cap
- ELAB 6.6M
- INDP 7.4M
- IPO Year
- ELAB 2023
- INDP N/A
- Fundamental
- Price
- ELAB $2.22
- INDP $0.50
- Analyst Decision
- ELAB
- INDP Strong Buy
- Analyst Count
- ELAB 0
- INDP 2
- Target Price
- ELAB N/A
- INDP $8.50
- AVG Volume (30 Days)
- ELAB 1.1M
- INDP 75.0K
- Earning Date
- ELAB 05-14-2025
- INDP 05-07-2025
- Dividend Yield
- ELAB N/A
- INDP N/A
- EPS Growth
- ELAB N/A
- INDP N/A
- EPS
- ELAB N/A
- INDP N/A
- Revenue
- ELAB N/A
- INDP N/A
- Revenue This Year
- ELAB N/A
- INDP N/A
- Revenue Next Year
- ELAB N/A
- INDP N/A
- P/E Ratio
- ELAB N/A
- INDP N/A
- Revenue Growth
- ELAB N/A
- INDP N/A
- 52 Week Low
- ELAB $2.15
- INDP $0.43
- 52 Week High
- ELAB $1,064.00
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- ELAB 27.63
- INDP 39.50
- Support Level
- ELAB $2.26
- INDP $0.45
- Resistance Level
- ELAB $2.96
- INDP $0.53
- Average True Range (ATR)
- ELAB 0.55
- INDP 0.04
- MACD
- ELAB 0.07
- INDP 0.01
- Stochastic Oscillator
- ELAB 2.06
- INDP 66.67
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.